Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

Sponsor
Steno Diabetes Center Copenhagen
Study ID
NCT03449654
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The objective of this study is to evaluate the mechanism behind the anti-atherogenic effects of liraglutide. In a randomized, placebo-controlled, double-blind, parallel trial we will included 100 patients with type 2 diabetes. Patients will be randomized 1:1 to an active treatment period of 26 weeks or placebo for 26 weeks. The primary endpoint is change from baseline to week 26 in vascular inflammation, assessed by Flour Deoxy Glucose (FDG)-Positron Emission Tomography/Computed Tomography (PET/CT)

Key Dates

Start date
Oct 26, 2017
Status verified
Jun 2020
Primary completion
Aug 16, 2019
Completion
Aug 16, 2019

Study Design

Enrollment
102 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Other: Liraglutide
  • Other: placebo

Primary Outcome Measure

Change in vascular inflammation [ Time Frame: baseline to week 26 ]

Related Studies